Significantly, we demonstrated that ILT4 inhibition reversed the immunosuppressive TME and might be a promising strategy for the second-line treatment of TKI-resistant EGFR-mutant NSCLC. This evidence concerns the gene LILRB2 and non-small cell lung carcinoma.